fibrosis

(redirected from Idiopathic pulmonary fibrosis)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

fibrosis

the formation of an abnormal amount of fibrous tissue in an organ or part as the result of inflammation, irritation, or healing

fibrosis

[fī′brō·səs]
(medicine)
Growth of fibrous connective tissue in an organ or part in excess of that naturally present.
References in periodicals archive ?
Idiopathic Pulmonary Fibrosis Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to idiopathic pulmonary fibrosis trends and structure of deals entered into by leading companies worldwide.
The first suspicion that a person may have idiopathic pulmonary fibrosis is usually based on the patient's symptoms and medical history.
I am pleased to read the insightful and thought-provoking comments of Dr Lederer and colleagues regarding a credible role for obstructive sleep apnea (OSA) in the etiology and pathogenesis of idiopathic pulmonary fibrosis (IPF).
A history of prior chest x-rays demonstrating progressive fibrosis over many years is a good hint for idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis Pipeline Molecules - Phase 3 Clinical Trial
Nintedanib* targets growth factor receptors, which have been shown to be potentially involved in the pathenogenesis of idiopathic pulmonary fibrosis, most importantly the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR).
A review of the Idiopathic Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
The survey involved 600 ILD patients (300 men/300 women), including 279 (47 percent) with idiopathic pulmonary fibrosis (IPF).
In pulmonology, we are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.
Inducible T-cell Costimulator (ICOS) Expression on CD4 T Cells Predicts Outcomes in Idiopathic Pulmonary Fibrosis Catherine A.
a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibroproliferative diseases, today announced that the United States Food and Drug Administration (FDA) Office of Orphan Products Development has granted an Orphan Drug designation to Promedior's lead drug candidate, PRM-151, for the treatment of idiopathic pulmonary fibrosis (IPF).
New Idiopathic Pulmonary Fibrosis Report Now Available from Decision Resources

Full browser ?